Beta Testing; Understanding Alzheimer's Disease  

Oleh:

[s.n]

Jenis: Article from Bulletin/Magazine
Dalam koleksi: The Economist (http://search.proquest.com/) vol. 407 no. 8841 (Jun. 2013), page 72-73.
Topik: Alzheimers Disease; Dementia; Medical Research; Pharmaceutical Industry; Research & Development--R&D

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: EE29 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

In America in 2010, the cost of treating those with dementia was $109 billion. That exceeds the cost of treating those with heart disease or with cancer. The RAND Corporation, a Californian think-tank, reckons this cost will more than double by 2040. A treatment for Alzheimer's is therefore needed for fiscal as well as humanitarian reasons. Experimental drugs intended to attack amyloid beta directly have proved disappointing. Last year clinical trials of the two most advanced such drugs did not slow the decline of most patients' memories--though solanezumab, from Eli Lilly, did yield some positive results in a group of patients whose Alzheimer's was mild. Testing drugs in this way--to find out if they can stop a disease from starting--is an ethical minefield because it means experimenting on people who are, to all intents and purposes, healthy. Many Alzheimer's drugs have seemed to succeed in animals, only to prove ineffective in people. Promising drugs have also been scuttled by safety problems or technical glitches.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali